There is nothing specific about PAR management rather the market has marked down PR for creating repetitious milestone ambiguity.
When it comes to investing and in particular biotechs you have to embrace the process and most importantly be willingly to shoulder the inherent uncertainty and pain that comes with it.
- Forums
- ASX - By Stock
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
There is nothing specific about PAR management rather the market...
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
28.5¢ |
Change
0.005(1.79%) |
Mkt cap ! $99.69M |
Open | High | Low | Value | Volume |
28.0¢ | 28.5¢ | 28.0¢ | $5.473K | 19.50K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15511 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 32821 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 15511 | 0.285 |
3 | 37881 | 0.280 |
4 | 32037 | 0.275 |
6 | 84309 | 0.270 |
3 | 517550 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 32821 | 5 |
0.295 | 3171 | 2 |
0.300 | 9158 | 4 |
0.305 | 3666 | 1 |
0.310 | 31789 | 2 |
Last trade - 10.48am 03/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online